Literature DB >> 22446992

Treatment update in multiple sclerosis.

Katrina Morris1, Con Yiannikas.   

Abstract

Multiple sclerosis is the most common cause of disability in young people in the Western world. Reduced life expectancy and worsening quality of life due to increasing disability later in the disease course have significant personal and societal costs. Changes in treatment strategies and newly available treatments hope to improve the outlook for our often young patients. This paper details currently available treatments and some that are expected to reach the market shortly.

Entities:  

Mesh:

Year:  2012        PMID: 22446992     DOI: 10.1007/s11882-012-0256-5

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  46 in total

Review 1.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

2.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

3.  Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency.

Authors:  J A Reekers; M J Lee; A M Belli; F Barkhof
Journal:  Cardiovasc Intervent Radiol       Date:  2010-12-07       Impact factor: 2.740

Review 4.  Clinical markers of therapeutic response to disease modifying drugs.

Authors:  Carlo Pozzilli; Luca Prosperini
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

Review 5.  Immunosuppression followed by immunomodulation.

Authors:  Mike Boggild
Journal:  J Neurol Sci       Date:  2009-02-01       Impact factor: 3.181

6.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

7.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

8.  Disease-modifying therapy in multiple sclerosis: update and clinical implications.

Authors:  Douglas S Goodin
Journal:  Neurology       Date:  2008-12-09       Impact factor: 9.910

Review 9.  Multiple sclerosis cerebrospinal fluid biomarkers.

Authors:  Gavin Giovannoni
Journal:  Dis Markers       Date:  2006       Impact factor: 3.434

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  3 in total

1.  Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.

Authors:  Leslie S Wilson; Aimee Loucks; Gregory Gipson; Lixian Zhong; Christine Bui; Elizabeth Miller; Mary Owen; Daniel Pelletier; Douglas Goodin; Emmanuelle Waubant; Charles E McCulloch
Journal:  Int J MS Care       Date:  2015 Mar-Apr

2.  TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.

Authors:  Emily Cheng; Cheryl L Armstrong; Rebeca Galisteo; Jeffrey A Winkles
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

3.  Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry.

Authors:  Alexandra Simbrich; Jasmine Thibaut; Laura Khil; Stanislav Maximov; Heinz Wiendl; Klaus Berger
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.